Navigation Links
Analysis of Venture Capital Investment Trends in the North American and European Healthcare Industry
Date:12/13/2012

MOUNTAIN VIEW, Calif., Dec. 13, 2012 /PRNewswire/ --

WHEN:

11:00 a.m. ET on Thursday, Dec. 20, 2012

LOCATION: 

Online, with complimentary registration

SPEAKER: 

Frost & Sullivan Business and Financial Services
Research Analyst Dr. E. Saneesh

In the current state of the global economy, in which fundraising has become tight and there are decreasing opportunities to exit, venture capital (VC) firms are extremely cautious in choosing their investments. This briefing will investigate the historical trends of VC investments and key areas of investment in the European and North American healthcare industry.

Why you should attend:

  • Learn about key trends in the VC industry
  • Discover the segments attracting VC investments in the European and North American healthcare industries
  • Participate in a live Q&A session with the analyst

This briefing will benefit VC, financial, private equity, and strategic investors, as well as startup companies.  This presentation will inform participants about key trends so investors are better positioned to make informed judgments before investing in specific segments or companies. 

Supporting Quote
"The pharmaceutical and biotechnology segments have become more mature, with a shift from VC investments to more strategic investments," said Frost & Sullivan Research Analyst Dr. E. Saneesh.  "This is shown by the decrease in the number of VC deals in these segments; however, the healthcare equipment segment has displayed increases in the number of investments. The consolidating VC industry has also contributed to the reduction in the number of VC deals globally."

Supporting Resources
For more information about Frost & Sullivan's Business and Financial Services practice, please visit: http://bit.ly/UElhNw.

Registration

  • To attend the briefing, email britni.myers@frost.com your full name, job title, company name, company telephone number, company email address and web site, city, state and country.
  • Receive a recorded version of the briefing anytime by submitting the aforementioned contact details.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. 

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.  
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible.  This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.  

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?  

Contact Us:     Start the discussion

Join Us:            Join our community

Subscribe:       Newsletter on "the next big thing" 

Register:        Gain access to visionary innovation

Contact:
Britni Myers
Frost & Sullivan
+1.210.477.8481
britni.myers@frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Genedata Expressionist® Established as Data Analysis Platform for Oncological Research
2. Rigaku ZSX Primus Application Note: Lubricating Oil Analysis by WDXRF According to ASTM D6443-04
3. Biocartis Announces Commercial Launch of a New Biomarker Analysis Platform
4. Sulfur Analysis in Crude Oil and High-Sulfur Fuels by WDXRF According to ASTM D2622-10
5. VisionGate Reports Advances In Its Cell-CT(TM) Automated 3D Cell Analysis Platform At ASC 2012 Scientific Meeting
6. Global Medical Image Analysis Software Market Worth $2.4 Billion by 2017
7. Recently Published Economic Analysis Highlights the Financial Impact of Attention-Deficit/Hyperactivity Disorder (ADHD) in the United States (US)
8. In massive genome analysis ENCODE data suggests gene redefinition
9. Surgical Equipment Market (Surgical Sutures, Surgical Hand Instruments And Electrosurgical Devices) - Global Forecast, Market Share, Size, Growth And Industry Analysis (2010-2017): Twease.org
10. New wave of technologies possible after ground-breaking analysis tool developed
11. Spectrometry Market (Atomic, Molecular and Mass Spectrometry) - Global Scenario, Trends, Industry Analysis, Size, Share & Forecast 2011 - 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... HACKENSACK, N.J. , Feb. 16, 2017  Champions ... engaged in the development and sale of advanced technology ... of oncology drugs, today announced the addition of new ... These new models will expand Champions, product ... cancer, head and neck cancer, AML, and non-small cell ...
(Date:2/16/2017)... 2017  Windtree Therapeutics, Inc. (Nasdaq: ... aerosolized KL4 surfactant therapies for respiratory diseases, announced ... showed that aerosolized KL4 surfactant reduced lung inflammation ... animal model. The Company believes that these preclinical ... that supports the role of KL4 surfactant as ...
(Date:2/16/2017)... and NEW YORK , Feb. ... near completion of their $7M Series B financing, adding ... of the $3.5M led by Mesa Verde Venture Partners ... These resources will be directed towards further accelerating commercial ... a comprehensive genomic profiling test and expanding the Paradigm ...
(Date:2/15/2017)... ... , ... Executive search firm, Slone Partners, announces the placement ... is a veteran life sciences and molecular diagnostics executive with extensive commercialization experience. ... disease risk in future generations. In his new role, Matt will be responsible ...
Breaking Biology Technology:
(Date:1/31/2017)... 31, 2017  Spero Therapeutics, LLC, a biopharmaceutical ... treatment of bacterial infections, today announced it has ... from Pro Bono Bio Ltd (PBB) to bolster ... resistant forms of Gram-negative bacteria.   The assets acquired ... a PBB group company. "The acquisition ...
(Date:1/26/2017)...  Acuity Market Intelligence today released the 2017 ...  Acuity characterizes 2017 as a "breakout" year for ... a new understanding of the potential benefits these ... identity are often perceived as threats to privacy ... of Acuity Market intelligence. "However, taken together these ...
(Date:1/24/2017)... -- It sounds simple and harmless—an electronic sensor attached ... and alerts parents on their smart phones if, ... But pediatric experts argue that such devices may ... of medical benefits, especially to healthy babies. ... of healthy babies, promising peace of mind about ...
Breaking Biology News(10 mins):